Short Term Liabilities: EOLS's short term assets ($95.2M) exceed its short term liabilities ($26.0M).
Long Term Liabilities: EOLS's short term assets ($95.2M) do not cover its long term liabilities ($139.6M).
Debt to Equity History and Analysis
Debt Level: EOLS's debt to equity ratio (429.4%) is considered high.
Reducing Debt: Insufficient data to determine if EOLS's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Inventory Level: EOLS has a low level of unsold assets or inventory.
Debt Coverage by Assets: EOLS's debt is covered by short term assets (assets are 1.3x debt).
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: EOLS has less than a year of cash runway based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if EOLS has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
What is Evolus's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Current dividend yield vs market & industry
Notable Dividend: Unable to evaluate EOLS's dividend yield against the bottom 25% of dividend payers, as the company has not reported any payouts.
High Dividend: Unable to evaluate EOLS's dividend yield against the top 25% of dividend payers, as the company has not reported any payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if EOLS's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if EOLS's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of EOLS's dividend in 3 years as they are not forecast to pay a notable one for the US market.
What is the CEO of Evolus's salary, the management and board of directors tenure and is there insider trading?
1.3yrs
Average management tenure
CEO
DavidMoatazedi(41yo)
1.6yrs
Tenure
US$5,794,178
Compensation
Mr. David Moatazedi has been the President, Chief Executive Officer and Director of Evolus, Inc. since joining it on May 6, 2018. Mr. Moatazedi served as Senior Vice President of Medical Aesthetics at Alle ...
CEO Compensation Analysis
Compensation vs Market: David's total compensation ($USD5.79M) is above average for companies of similar size in the US market ($USD1.71M).
Compensation vs Earnings: Insufficient data to compare David's compensation with company performance.
Management Age and Tenure
1.3yrs
Average Tenure
49yo
Average Age
Experienced Management: EOLS's management team is not considered experienced ( 1.3 years average tenure), which suggests a new team.
Board Age and Tenure
1.9yrs
Average Tenure
55.5yo
Average Age
Experienced Board: EOLS's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.
Insider Trading
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
BuyUS$27,30015 Jun 19
David Gill
Entity
Individual
Role
Member of the Board of Directors
Independent Director
Shares
2,000
Max Price
US$13.65
BuyUS$24,999,99404 Jun 19
Vikram Malik
Entity
Individual
Role
Chairman of the Board
Chairman of the Board
Shares
1,298,701
Max Price
US$19.25
SellUS$24,999,99404 Jun 19
ALPHAEON Corporation
Entity
Company
Shares
1,298,701
Max Price
US$19.25
BuyUS$30,86331 May 19
Kristine Romine
Entity
Individual
Role
Member of the Board of Directors
Independent Director
Shares
2,090
Max Price
US$14.77
SellUS$35,35231 May 19
Lauren Silvernail
Entity
Individual
Role
Chief Financial Officer
CFO & Executive VP of Corporate Development
Shares
2,612
Max Price
US$13.53
BuyUS$780,81922 May 19
Kristine Romine
Entity
Individual
Role
Member of the Board of Directors
Independent Director
Shares
40,562
Max Price
US$19.25
BuyUS$12,099,31822 May 19
Simone Blank
Entity
Individual
Role
Member of the Board of Directors
Director
Shares
628,536
Max Price
US$19.25
SellUS$102,177,84522 May 19
ALPHAEON Corporation
Entity
Company
Shares
5,307,940
Max Price
US$19.25
BuyUS$201,20418 Dec 18
Kristine Romine
Entity
Individual
Role
Member of the Board of Directors
Independent Director
Shares
16,000
Max Price
US$12.75
BuyUS$38,30018 Dec 18
David Gill
Entity
Individual
Role
Member of the Board of Directors
Independent Director
Shares
3,000
Max Price
US$12.77
BuyUS$101,68918 Dec 18
Vikram Malik
Entity
Individual
Role
Chairman of the Board
Chairman of the Board
Shares
7,800
Max Price
US$13.04
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 26.3%.
Management Team
Lauren Silvernail (60yo)
CFO & Executive VP of Corporate Development
Tenure: 1.6yrs
Compensation: US$3.83m
David Moatazedi (41yo)
President
Tenure: 1.6yrs
Compensation: US$5.79m
Rui Avelar (57yo)
Chief Medical Officer and Head of Research & Development
Tenure: 5.9yrs
Compensation: US$365.00k
Jeff Plumer
Vice President of Legal
Tenure: 0yrs
Mike Jafar (38yo)
Chief Marketing Officer
Tenure: 1.5yrs
Compensation: US$3.93m
Ashwin Agarwal
Vice President of Finance
Tenure: 1.3yrs
Kurt Knab
President of Sales
Tenure: 1.2yrs
Alex Sabad
Vice President of Operations
Tenure: 1.2yrs
Amy Fox
Vice President of Human Resources
Tenure: 1.2yrs
Crystal Muilenburg
Vice President of Corporate Communications & Public Relations
Tenure: 0.8yrs
Board Members
Peter Farrell (77yo)
Independent Director
Tenure: 0.4yrs
David Gill (64yo)
Independent Director
Tenure: 1.8yrs
Compensation: US$148.41k
Simone Blank (55yo)
Director
Tenure: 1.9yrs
Compensation: US$154.49k
Bosun Hau
Independent Director
Tenure: 1.9yrs
Compensation: US$154.49k
Robert Hayman (60yo)
Independent Director
Tenure: 1.9yrs
Compensation: US$150.07k
Vik Malik (56yo)
Chairman of the Board
Tenure: 1.9yrs
Compensation: US$158.90k
Karah Parschauer (41yo)
Independent Director
Tenure: 0.4yrs
David Moatazedi (41yo)
President
Tenure: 1.6yrs
Compensation: US$5.79m
Kristine Romine (54yo)
Independent Director
Tenure: 1.9yrs
Compensation: US$150.07k
Company Information
Evolus, Inc.'s company bio, employee growth, exchange listings and data sources
Evolus, Inc., a performance beauty company, provides medical aesthetic products for physicians and their patients in the United States. It offers Jeuveau, a proprietary 900 kilodalton purified botulinum to ...
Company Analysis and Financial Data Status
All financial data provided by Standard & Poor's Capital IQ.
Data
Last Updated (UTC time)
Company Analysis
2019/12/08 01:05
End of Day Share Price
2019/12/06 00:00
Earnings
2019/09/30
Annual Earnings
2018/12/31
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.